Skip to main content
Top
Published in: Breast Cancer 6/2018

01-11-2018 | Original Article

Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists

Authors: Toru Morioka, Naoki Niikura, Nobue Kumaki, Shinobu Masuda, Takayuki Iwamoto, Kozue Yokoyama, Rin Ogiya, Risa Oshitanai, Mayako Terao, Banri Tsuda, Takuho Okamura, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda

Published in: Breast Cancer | Issue 6/2018

Login to get access

Abstract

Background

Routine analysis of Ki-67 is not widely recommended for clinical decision-making because of poor reproducibility. Furthermore, counting numerous cells can be laborious for pathologists. Digital image analysis for immunohistochemical analysis was recently developed; however, the clinical efficacy of the Ki-67 index obtained using image analysis is unknown.

Methods

We retrospectively identified female patients with breast cancer with immunohistochemical Ki-67 and survival data using the pathology database at the Tokai University, Japan. Ki-67 expression was scored by three pathologists. Slides were scanned and converted to virtual slides; Ki-67-positive cells were counted using image analysis. Ki-67 indices obtained by the pathologist’s scoring and image analysis were evaluated by 2 × 2 analysis. Relationships between Ki-67 index and survival outcomes were evaluated using the Kaplan–Meier method and compared using the log-rank test.

Results

Based on the 2 × 2 analysis, Ki-67 index obtained using image analysis was moderately correlated with the pathologist’s scoring for all patients (κ 0.41; sensitivity, 0.573; specificity, 0.878). Poorer relapse-free survival was associated with high Ki-67 index than with low Ki-67 index for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and stage I or II patients scored by pathologists (p < 0.001) and obtained using image analysis (p = 0.031).

Conclusions

The Ki-67 indices obtained using image analysis were moderately correlated with those scored by pathologists. Digital image analysis can be effective for measuring Ki-67 values, because they are associated with relapse-free survival in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and patients at stage I or II.
Literature
1.
go back to reference Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N, et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer. 2014;23:92–100.CrossRef Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N, et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer. 2014;23:92–100.CrossRef
2.
go back to reference Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–64.CrossRef Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–64.CrossRef
3.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.CrossRef Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.CrossRef
4.
go back to reference Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–906.CrossRef Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–906.CrossRef
5.
go back to reference Harris LN, Ismaila N, McShane LM, Hayes DF. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline summary. J Oncol Pract. 2016;12:384–9.CrossRef Harris LN, Ismaila N, McShane LM, Hayes DF. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline summary. J Oncol Pract. 2016;12:384–9.CrossRef
6.
go back to reference Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRef Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRef
7.
go back to reference Vörös A, Csörgő E, Kővári B, Lázár P, Kelemen G, Cserni G. The use of digital images improves reproducibility of the Ki-67 labeling index as a proliferation marker in breast cancer. Pathol Oncol Res. 2014;20:391–7.CrossRef Vörös A, Csörgő E, Kővári B, Lázár P, Kelemen G, Cserni G. The use of digital images improves reproducibility of the Ki-67 labeling index as a proliferation marker in breast cancer. Pathol Oncol Res. 2014;20:391–7.CrossRef
8.
go back to reference Maeda I, Abe K, Koizumi H, Nakajima C, Tajima S, Aoki H, et al. Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer. Breast Cancer. 2016;23:745–51.CrossRef Maeda I, Abe K, Koizumi H, Nakajima C, Tajima S, Aoki H, et al. Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer. Breast Cancer. 2016;23:745–51.CrossRef
9.
go back to reference Røge R, Riber-Hansen R, Nielsen S, Vyberg M. Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining. Breast Cancer Res Treat. 2016;158:11–9.CrossRef Røge R, Riber-Hansen R, Nielsen S, Vyberg M. Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining. Breast Cancer Res Treat. 2016;158:11–9.CrossRef
10.
go back to reference Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M, et al. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol. 1996;49:926–30.CrossRef Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M, et al. MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol. 1996;49:926–30.CrossRef
11.
go back to reference Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71:146–9.CrossRef Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71:146–9.CrossRef
12.
go back to reference Stalhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Mølholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.CrossRef Stalhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Mølholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.CrossRef
13.
go back to reference Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer. 2000;89:111–17.CrossRef Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer. 2000;89:111–17.CrossRef
14.
go back to reference Thomson CS, Twelves CJ, Mallon EA, Leake RE, Scottish Cancer Trials Brest Group, Scottish Cancer Therapy Network. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast. 2002;11:419–29.CrossRef Thomson CS, Twelves CJ, Mallon EA, Leake RE, Scottish Cancer Trials Brest Group, Scottish Cancer Therapy Network. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast. 2002;11:419–29.CrossRef
15.
go back to reference Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, et al. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571–81.CrossRef Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, et al. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571–81.CrossRef
16.
go back to reference Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol. 2007;15:325–31.CrossRef Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol. 2007;15:325–31.CrossRef
17.
go back to reference Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–52.CrossRef Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–52.CrossRef
18.
go back to reference Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–65.CrossRef Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–65.CrossRef
19.
go back to reference Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol. 2008;26:1404–10.CrossRef Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol. 2008;26:1404–10.CrossRef
20.
go back to reference Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer. 2014;14:323–9.e3.CrossRef Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer. 2014;14:323–9.e3.CrossRef
21.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRef Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRef
22.
go back to reference Konsti J, Lundin M, Joensuu H, et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol. 2011;11:3.CrossRef Konsti J, Lundin M, Joensuu H, et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol. 2011;11:3.CrossRef
23.
go back to reference Arihiro K, Oda M, Ohara M, et al. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Jpn J Clin Oncol. 2016;46(12):1081–7.PubMed Arihiro K, Oda M, Ohara M, et al. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. Jpn J Clin Oncol. 2016;46(12):1081–7.PubMed
24.
go back to reference Klauschen F, Wienert S, Schmitt WD, et al. Standardized Ki67 diagnostics using automated scoring–clinical validation in the GeparTrio Breast Cancer study. Clin Cancer Res. 2015;21:3651–7.CrossRef Klauschen F, Wienert S, Schmitt WD, et al. Standardized Ki67 diagnostics using automated scoring–clinical validation in the GeparTrio Breast Cancer study. Clin Cancer Res. 2015;21:3651–7.CrossRef
Metadata
Title
Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists
Authors
Toru Morioka
Naoki Niikura
Nobue Kumaki
Shinobu Masuda
Takayuki Iwamoto
Kozue Yokoyama
Rin Ogiya
Risa Oshitanai
Mayako Terao
Banri Tsuda
Takuho Okamura
Yuki Saito
Yasuhiro Suzuki
Yutaka Tokuda
Publication date
01-11-2018
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0885-1

Other articles of this Issue 6/2018

Breast Cancer 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine